ASH: Novo’s Etavopivat For Sickle Cell Disease Cuts VOC Rates In Half
Phase III Ongoing, Endpoints Under Discussion With Regulators
Patients treated with Novo’s PKR activator had a nearly 50% reduction in vaso-occlusive events relative to placebo in Phase II, VOC occurrence was delayed and blood biomarkers improved.
